

Table 5.6
Immunosuppression Use for Maintenance
Prior to Discharge, 1998 to 2007
Recipients with Kidney Transplants

| | Year of Transplant | | | | | | | | | |
|---------------------------------------|--------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 |
| Functioning Graft at Discharge | 12,002 | 12,280 | 13,106 | 13,815 | 14,323 | 14,692 | 15,540 | 16,012 | 16,673 | 16,252 |
| With Immunosuppression Info | 11,933 | 12,093 | 12,889 | 13,790 | 14,259 | 14,617 | 15,407 | 15,786 | 16,466 | 15,884 |
| Corticosteroids | | | | | | | | | | |
| Any in Category | 96.6% | 97.3% | 95.7% | 93.6% | 91.2% | 84.7% | 77.3% | 73.0% | 67.7% | 65.9% |
| Steroids | 96.6% | 97.3% | 95.7% | 93.6% | 91.2% | 84.7% | 77.3% | 73.0% | 67.7% | 65.9% |
| Cyclosporine | | | | | | | | | | |
| Any in Category | 67.7% | 61.5% | 51.1% | 37.5% | 29.8% | 25.8% | 21.1% | 14.8% | 11.9% | 10.1% |
| Cyclosporin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% | 0.1% | 0.2% |
| Sandimmune | 5.4% | 5.3% | 3.1% | 2.5% | 1.4% | 0.9% | 0.7% | 0.5% | 0.5% | 0.4% |
| Neoral | 62.2% | 55.9% | 47.0% | 30.2% | 21.7% | 19.2% | 14.4% | 9.6% | 7.7% | 7.2% |
| Gengraf | 0.0% | 0.2% | 0.9% | 4.7% | 6.5% | 5.7% | 5.8% | 4.5% | 3.6% | 2.3% |
| Eon | 0.0% | 0.0% | 0.0% | 0.1% | 0.2% | 0.1% | 0.1% | 0.1% | 0.0% | 0.1% |
| Tacrolimus | | | | | | | | | | |
| Any in Category | 26.4% | 32.9% | 44.1% | 56.4% | 63.8% | 66.8% | 72.0% | 78.9% | 82.5% | 85.4% |
| Tacrolimus | 26.4% | 32.9% | 44.1% | 56.4% | 63.8% | 66.8% | 72.0% | 78.9% | 82.5% | 85.4% |
| Antimetabolites | | | | | | | | | | |
| Any in Category | 85.2% | 86.2% | 80.2% | 79.7% | 82.2% | 82.8% | 83.7% | 87.7% | 88.8% | 92.1% |
| Mycophenolate Mofetil | 72.9% | 78.1% | 74.8% | 75.5% | 79.4% | 80.4% | 80.8% | 82.0% | 75.9% | 75.0% |
| Mycophenolate Sodium | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | 0.5% | 1.6% | 5.0% | 12.0% | 16.4% |
| Azathioprine | 12.1% | 7.8% | 5.3% | 4.1% | 2.3% | 1.8% | 1.3% | 0.6% | 0.9% | 0.6% |
| Leflunomide | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cytosan | 0.1% | 0.2% | 0.2% | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| mTOR Inhibitors | | | | | | | | | | |
| Any in Category | 3.2% | 3.0% | 13.2% | 17.3% | 15.5% | 15.7% | 12.6% | 9.3% | 8.7% | 5.2% |
| Sirolimus | 3.0% | 2.5% | 13.0% | 17.2% | 14.9% | 15.7% | 12.4% | 9.0% | 8.2% | 4.8% |
| Everolimus | 0.2% | 0.4% | 0.2% | 0.1% | 0.6% | 0.0% | 0.2% | 0.3% | 0.5% | 0.4% |

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.